U.S. market Closed. Opens in 1 day 9 hours 46 minutes

INZY | Inozyme Pharma, Inc. Stock Overview

(Stock Exchange: NASDAQ)
Day's Range 4.89 - 5.32
52 Week Range 2.6890 - 7.80
Beta 1.24
Implied Volatility 167.32%
IV Rank 20.14%
Day's Volume 166,361
Average Volume 310,640
Shares Outstanding 62,734,400
Market Cap 312,417,312
Sector Healthcare
Industry Biotechnology
IPO Date 2020-07-24
Valuation
Profitability
Growth
Health
P/E Ratio -3.46
Forward P/E Ratio N/A
EPS -1.44
1YR Price Target N/A
Dividend Yield N/A
Dividend Per Share N/A
Dividend ExDate N/A
Dividend PayDate N/A
Employees 59
Country USA
Website INZY
Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as for the treatment of calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. Inozyme Pharma, Inc. was incorporated in 2015 and is headquartered in Boston, Massachusetts.
*Chart delayed
Analyzing fundamentals for INZY we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is weak. For more detailed analysis please see INZY Fundamentals page.

Watching at INZY technicals we can see that long-term trend is bullish, while middle-term trend is bearish, but short-term trend is bullish. More technicals details can be found on INZY Technicals page.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙